Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Public ClinicalTrials.gov record NCT04438382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.
Study identification
- NCT ID
- NCT04438382
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Interventions
- Infliximab Biological
- Intravenous Immunoglobulin Therapy Biological
- Prednisone Drug
- Methylprednisolone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2021 (Actual)
- Primary completion
- Dec 21, 2023 (Actual)
- Completion
- May 26, 2026 (Actual)
- Last update posted
- Sep 29, 2026
2021 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 6
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
| Bronson Battle Creek | Battle Creek | Michigan | 49017 | — |
| Mercy Health Saint Mary's | Grand Rapids | Michigan | 49503 | — |
| Spectrum Health at Butterworth Campus | Grand Rapids | Michigan | 49503 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007 | — |
| Mercy Health Mercy Campus | Muskegon | Michigan | 49444 | — |
| Lakeland Hospital Niles | Niles | Michigan | 49120 | — |
| Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores | Michigan | 49444 | — |
| Spectrum Health Reed City Hospital | Reed City | Michigan | 49677 | — |
| Lakeland Medical Center Saint Joseph | Saint Joseph | Michigan | 49085 | — |
| Marie Yeager Cancer Center | Saint Joseph | Michigan | 49085 | — |
| Munson Medical Center | Traverse City | Michigan | 49684 | — |
| Metro Health Hospital | Wyoming | Michigan | 49519 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| VCU Massey Cancer Center at Stony Point | Richmond | Virginia | 23235 | — |
| Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04438382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04438382 live on ClinicalTrials.gov.